Calculate the magnetic field and its direction at point P, which is 2.0 cm away from the top wire and 4.0 cm from the bottom wire. Assume both wires are infinitely long and each carries a current of 1.5 A.

Ajet plane has a sound level of 120 db at a distance of 60 m. what is the q23. sound level at a distance of 6.0 km? (60)2 (6000)? om solution 80db db, hint: 16x assume ultrasound waves travel through the body of an animal at 1540 q24. m/s. if a 30,000 hz signal were reflected off a portion of a heart which was moving toward the source at 3 m/s, what frequency signal would return to the stationary source? solution 30.117hz

The frequency of vibrations of a vibrating violin string is given by f = 1 2l t ρ where l is the length of the string, t is its tension, and ρ is its linear density.† (a) find the rate of change of the frequency with respect to the following. (i) the length (when t and ρ are constant) (ii) the tension (when l and ρ are constant) (iii) the linear density (when l and t are constant) (b) the pitch of a note (how high or low the note sounds) is determined by the frequency f. (the higher the frequency, the higher the pitch.) use the signs of the derivatives in part (a) to determine what happens to the pitch of a note for the following. (i) when the effective length of a string is decreased by placing a finger on the string so a shorter portion of the string vibrates df dl 0 and l is ⇒ f is ⇒ (ii) when the tension is increased by turning a tuning peg df dt 0 and t is ⇒ f is ⇒ (iii) when the linear density is increased by switching to another string df dρ 0 and ρ is ⇒ f is ⇒

Asubject in a clinical research trial experiences a serious, unanticipated adverse drug experience. how should the investigator proceed, with respect to the irb, after the discovery of the adverse event occurrence? a. do not report the adverse drug experience to the irb since it is a common adverse experience.b. report the adverse drug experience to the irb only if there are several other occurrences.c. report the adverse drug experience as part of the continuing review report.d. report the adverse drug experience in a timely manner, in keeping with the irb's policies and procedures, using the forms or the mechanism provided by the irb.